team_ttp_network_uk, Author at TTP Network

TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP

UncategorizedBy team_ttp_network_uk November 12, 2020

TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP Nice have today published the following decision: Caplacizumab with plasma exchange and immunosuppression is recommended, within its marketing authorisation, as an option for treating an acute episode of acquired thrombotic thrombocytopenic purpura (TTP) in adults, and in young people…

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

ArticlesBy team_ttp_network_uk October 23, 2020

Pregnancy and postpartum are high-risk periods for different forms of thrombotic microangiopathy (TMA). However, the management of pregnancy-associated TMA remains ill-defined…

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura

ArticlesBy team_ttp_network_uk October 23, 2020

Thrombotic thrombocytopenic purpura (TTP) is a rare thrombomicroangiopathy caused by deficiency of ADAMTS13. Acute neurological involvement is well described, but its long‐term impact requires evaluation. One‐hundred thirty‐one patients, following an acute TTP event, with severe headache or neurological symptoms had a cerebral MRI…

Author Archives: team_ttp_network_uk

TTPNetwork’s response to the NICE Decision on the use of Caplacizumab in the treatment of TTP

Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group

Cerebral MRI findings predict the risk of cognitive impairment in thrombotic thrombocytopenic purpura